Purple carrots, plums help people lose weight: USQ research

Topics:  editors picks, purple carrot, university of southern queensland, usq

Honor Tremain
15th Feb 2014 5:01 AM

Taylor Osmond, 22, with a bunch of purple carrots that research has shown is great for health and for losing weight. Robyne Cuerel

PURPLE foods may be the key to unlocking the obesity crisis, high blood pressure, cardiovascular disease and a host of other health disasters, according to new USQ research.
Laboratory tests showed that when purple carrots and the queen garnet plum were introduced to test subjects eating a high saturated fat, high sugar diet – similar to our Western diet – weight loss and much more occurred.
Not only did the subject lose weight, both foods had the startling ability to lower a wide range of related health disorders in the subjects.
Professor Lindsay Brown of the University of Southern Queensland said: “When the purple carrots or queen garnet plums were ingested, even in the presence of eating a high fat, high sugar diet, weight loss occurred.
“Not only that, but heart health improved, liver function and architecture were normalised, blood pressure returned to normal, and glucose was taken up normally by the body once more.”
Why purple foods? They contain anthocyanins, powerful anti-inflammatory compounds, which also give the foods their purple colour.
The groundbreaking discoveries were made by Prof Brown and his world-class research team, the Metabolic Syndrome Research Team, with Dr Sunil Panchal and Dr Hemant Poudyal.
Anthocyanins work by theoretically blocking NF-kB, one of the main factors responsible for the progression of the inflammation underpinning most modern diseases, including obesity.
Purple carrots were known in ancient Persia and Afghanistan more than 2000 years ago, long before their orange counterparts.
They appear to glean their power from these remarkable antioxidants: the anthocyanins.
More recently, Professor Brown, Dr Panchal and Mr. Maharshi Bhaswant worked together with local growers and the Queensland Government to test the queen garnet plum, possibly the next “super food”.
The plum was developed by the Department of Agriculture, Fisheries and Forestry (DAFF) and grown at Warroo Orchard in southern Queensland.
“The results are amazingly positive,” Prof Brown said.
They will visit the Hervey Bay USQ campus in July 2014.
Dietary suggestions are recommended as a complementary medicine. Please do not stop taking any prescribed medication without consulting your doctor first.
Find nutritionist Honor Tremain on Facebook at Honor Tremain Thriving Nutrition or to ask her a health or diet-related question, email honnutrition@hotmail.com.

Ipswich jobs listed daily

Feature your local job listings here today.Call 1300 136 181 or Post Your Ad

More Americans Getting High Blood Pressure Under Control: CDC

It is possible that you used an outdated or expired MedicineNet link or you may have typed the address incorrectly.
Please try searching using the search field above. If you’re not sure of the spelling, type the first few letters, followed by an asterisk(*).
To help you find what you are looking for, these links may help.

Opsumit approved by SwissMedic for pulmonary arterial hypertension

ALLSCHWIL/BASEL, SWITZERLAND – 14 February 2014 – Actelion Ltd (ATLN.VX) announced today that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.
Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality. Opsumit is effective when used as monotherapy or in combination with phosphodiesterase-5 inhibitors or inhaled / oral prostanoids. Jean-Paul Clozel, Chief Executive Officer of Actelion commented; “The SwissMedic approval, as one of the reference health authorities, is another positive step for Actelion and Opsumit in the global approval process. We are very proud that the convincing data from the SERAPHIN study and the translation into a label today, means that patients with PAH here in Switzerland can be treated with Opsumit. We will cooperate with the Swiss authorities to ensure availability for patients in due course.” The SwissMedic approval was based on data from the landmark Phase III SERAPHIN study. In the SERAPHIN study, treatment with macitentan 10 mg resulted in a 45% risk reduction (hazard ratio 0.55; 97.5% CI: 0.39 to 0.76; logrank p
The most commonly reported adverse drug reactions are nasopharyngitis (14%), headache (14%) and anaemia (13%). The majority of adverse reactions are mild to moderate in intensity.     ###   ABOUT OPSUMIT® (MACITENTAN) Opsumit (macitentan) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target of developing an ERA to address efficacy and safety [2,3]. ABOUT THE SERAPHIN STUDY SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) was the largest and longest randomized, controlled study in PAH patients to include a clearly defined morbidity/mortality primary endpoint [1]. The pivotal Phase III study was designed to evaluate the efficacy and safety of Opsumit (macitentan) – a novel dual endothelin receptor antagonist that resulted from a tailored drug discovery process – through the primary endpoint of time to first morbidity and all-cause mortality event in patients with symptomatic PAH. Global enrolment was completed in December 2009 with a total of 742 patients. Patients were randomized 1:1:1 to receive two different doses of macitentan (3 mg and 10 mg once daily) or placebo. Patients were allowed to receive PAH background therapy throughout the study, either PDE-5 inhibitors or oral/inhaled prostanoids. This event-driven study was conducted in 151 centers from almost 40 countries in North America, Latin America, Europe, Asia-Pacific and Africa and was completed in the first half of 2012, with 287 patients having an adjudicated event. ABOUT SERAPHIN STUDY DATA Patients were randomized to placebo (n=250), macitentan 3 mg (n=250), or macitentan 10 mg (n=242). The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, respectively. The hazard ratio for macitentan 3 mg versus placebo was 0.70 (97.5% CI, 0.52 to 0.96; p=0.0108) and the hazard ratio for macitentan 10 mg versus placebo was 0.55 (97.5% CI, 0.39 to 0.76; p
ABOUT THE SAFETY AND TOLERABILITY PROFILE The most commonly reported adverse drug reactions with Opsumit are nasopharyngitis (14.0%), headache (13.6%) and anaemia (13.2%).  ABOUT OPSUMIT (MACITENTAN) SUBMISSIONS TO HEALTHCARE AUTHORITIES The first approval globally of the new drug application for Opsumit (macitentan) was issued by the US Food and Drug Administration (FDA) on 18 October 2013 for the treatment of pulmonary arterial hypertension. Opsumit (macitentan) is also approved for PAH in the EU, Canada, and Australia.  Regulatory reviews in other countries are ongoing. ABOUT PULMONARY ARTERIAL HYPERTENSION [4, 5, 6] Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The symptoms of PAH are non-specific and can range from mild breathlessness and fatigue during normal daily activity to symptoms of right heart failure and severe restrictions on exercise capacity and ultimately reduced life expectancy. PAH is one group within the classification of pulmonary hypertension (PH). This group includes idiopathic PAH, heritable PAH and PAH caused by factors which include connective tissue disease, HIV infection and congenital heart disease. The last decade has seen significant advances in the understanding of the pathophysiology of PAH, which has been paralleled with developments of treatment guidelines and new therapies. Drugs targeting the three pathways that have been established in the pathogenesis of PAH are endothelin receptor antagonists (ERAs), prostacyclins and phosphodiesterase-5 inhibitors. PAH treatments have transformed the prognosis for PAH patients from symptomatic improvements in exercise tolerance 10 years ago to delayed disease progression today. Improved disease awareness and evidence-based guidelines developed from randomized controlled clinical trial data have highlighted the need for early intervention, goal-oriented treatment and combination therapy. In PAH, survival rates are unacceptably low and PAH remains incurable.   References
Pulido T et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013;369:809-18. Bolli MH et al. The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N`-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist. J Med Chem. 2012; 55:7849-61. Iglarz M. et al. Pharmacology of macitentan, an orally active tissue targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736-745. Proceedings of the 4th world symposium on pulmonary hypertension. J Am CollCardiol 2009;54(1 Suppl). Galiè N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL. Chest 2012;142:448-56.
  Actelion Ltd. Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma. Founded in late 1997, with now close to 2,400 dedicated professionals covering all key markets around the world including the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.   For further information please contact: Roland Haefeli Senior Vice President, Head of Investor Relations & Public Affairs Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 +1 650 624 69 36www.actelion.com The above information contains certain “forward-looking statements”, relating to the company`s business, which can be identified by the use of forward-looking terminology such as “estimates”,  “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,  “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions.  Such statements include descriptions of the company`s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company`s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Press Release PDF

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: Actelion Pharmaceuticals Ltd via GlobeNewswireHUG#1761824

Health Care Industry
Health
pulmonary hypertension
SwissMedic
endothelin receptor antagonist

Resistant hypertension clinic treating patients when meds fail

[unable to retrieve full-text content]

-High blood pressure is an epidemic in Louisiana and 25 percent of those with hypertension have a resistant form of the disease. A resistant hypertension clinic at Lake Charles Memorial Hospital’s Heart & Vascular Center is treating patients when they …

Blood pressure in young adults may predict heart disease

[unable to retrieve full-text content]

Having elevated or rising blood pressure in young adulthood may signal a higher risk for heart disease in middle age, a study by researchers at Northwestern University found. The researchers analyzed blood pressure patterns of about 5,000 men and women …and more »

Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.

SAN DIEGO, Feb. 10, 2014 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires’ lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension. 

“The acquisition of Aires will enhance our pipeline with a phase 2 asset with more than 120 human subject exposures and which is a strategic complement to our lead program, MST-188. With total consideration of approximately 6% of Mast equity, it represents excellent value for our stockholders,” stated Brian M. Culley, Chief Executive Officer of Mast Therapeutics, Inc.

“Nitrite has demonstrable beneficial properties, including vasodilation and the reduction of inflammation and undesirable cell growth. These are important therapeutic objectives and an ideal complement to MST-188 and its ability to improve blood flow and seal cellular membranes. In addition, we intend to investigate the hypothesis that AIR001 positively affects mitochondrial activity and myocyte energetics. With this acquisition, and the initiation of our phase 2 trial of MST-188 for the treatment of acute limb ischemia later this quarter, we are taking additional steps towards building a sustainable company with a valuable pipeline addressing significant unmet needs in both specialized and major markets,” Mr. Culley continued.

“Another highlight of this acquisition is its favorable economics. Aires had completed several venture financings, including a $20 million Series B round. We are paying significantly less than that to acquire the program and we currently estimate that our development costs for AIR001 for the first 12 months will be approximately $2 million.  Our estimated costs for AIR001 will change as we refine our development strategy over the next few months, but Aires is expected to contribute approximately $3 million of net cash at the closing of the merger, so, as currently contemplated, our first year of development of AIR001 will not require additional capital investment by Mast,” Mr. Culley concluded.

Under the terms of the all-stock transaction, Aires would become a wholly-owned subsidiary of Mast Therapeutics, Inc. in exchange for shares of Mast common stock representing approximately 6% of Mast’s outstanding common stock, 80% of which would be subject to a six-month holdback for certain indemnification claims of Mast. There are no milestone obligations payable to Aires.  The acquisition is expected to close in February 2014, subject to customary closing conditions.

About AIR001
AIR001 (sodium nitrite) inhalation solution, also known as Aironite®, is an intermittently nebulized formulation of nitrite. Under hypoxic conditions, AIR001 is converted to nitric oxide.  Nitrite mediated nitric oxide formation has several beneficial effects, including dilation of blood vessels and reduction of inflammation and undesirable cell growth. 

AIR001 has been granted orphan drug status by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.

Conference Call Information
Interested parties may access the conference call by dialing (877) 870-4263 from the U.S. and (412) 317-0790 from outside the U.S. and should request the Mast Therapeutics Corporate Update Call. The webcast will be available live via the Internet by accessing the Investors section of Mast’s website at www.masttherapeutics.com/investors/. Replays of the webcast will be available on the Company’s website for 30 days and a phone replay will be available through March 5, 2014 by dialing (877) 344-7529 from the U.S. and (412) 317-0088 from outside the U.S. and entering conference reference number 10040517. 

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). 

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease.  In the first quarter of 2014, the Company plans to initiate a phase 2, clinical proof of concept study in acute limb ischemia that will evaluate whether MST-188 improves the effectiveness of existing thrombolytic agents. The Company is also evaluating development options for MST-188 in heart failure. More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.  Aironite® is a trademark of Aires Pharmaceuticals, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to the completion of the acquisition of Aires Pharmaceuticals, the amount of the Company’s common stock issuable as merger consideration, the amount of Aires’ net cash at closing of the merger, the Company’s development plans for AIR001, as well as the cost and timing of activities related to those plans, and the Company’s development plans for MST-188 in acute limb ischemia and heart failure, including the timing of initiation of any clinical studies.  Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the potential that the acquisition may be delayed and/or terminated; the potential that the number of shares of the Company’s common stock issuable to Aires’ stockholders as merger consideration will be greater or less than the Company’s estimated amount as a result of differences between the Company’s estimate of and Aires’ actual net cash at closing and/or the volatility in the closing sales prices of the Company’s common stock; the uncertainty of outcomes in ongoing and future studies of any investigational drug, including MST-188 and AIR001, and the risk that they may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including EPIC; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a “clinical hold,” and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of any planned phase 2 clinical study of MST-188 or AIR001; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the Company’s reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of its product candidates, including clinical studies and regulatory activities for MST-188, and that such third parties may fail to perform as expected; the Company’s ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success with its products and may never generate revenue sufficient to achieve profitability; the risk that the Company is not able to adequately protect its intellectual property rights relating to the MAST platform and MST-188, and, following the acquisition, AIR001, and prevent competitors from duplicating or developing equivalent versions of its product candidates; and other risks and uncertainties more fully described in the Company’s press releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law. 

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)

CardioBuzz: What HIV and High BP Have in Common

[unable to retrieve full-text content]

HIV infection is a sexually transmitted infectious disease; hypertension is neither of these things. HIV is a major global health priority and is recognized as a serious threat to public health and development in many poorer countries. Hypertension is …High Blood Pressure, the New HIV Epidemic?Ivanhoeall 3 news articles »

High Blood Pressure

Hypertensive patients’ use of specialty services changed with primary care resdesign

Group Health studied how patients with treated hypertension used outpatient specialty care before, during, and after a primary-care redesign (the patient-centered medical home) was spread system-wide. David T. Liss, PhD, now a research assistant professor in medicine-general internal medicine and geriatrics at Northwestern University Feinberg School of Medicine, led the report in the Journal of General Internal Medicine.

“Redesigning care to a medical home seems to let primary-care teams do more, within their expertise, for their patients,” Dr. Liss said. “Our results suggest this can avoid or prevent some specialty visits for patients with stable hypertension and a few co-occurring illnesses.” He studied more than 36,000 patients with treated hypertension in Group Health’s 26 medical centers.

Patients with hypertension and few other conditions had 27-28 percent fewer specialty visits in each of the three years after the medical home started being implemented, compared to beforehand, adjusting for potential confounders and including interaction effects. Those with some other illnesses had 9 percent fewer specialty visits during medical home implementation and 5 percent fewer specialty visits during the following year.

“In contrast, we found very different results for clinically complex patients burdened by multiple diseases in addition to hypertension,” said Dr. Liss’s coauthor Robert Reid, MD, PhD, a senior investigator at Group Health Research Institute, , and an adjunct professor at the University of Washington (UW) School of Public Health and Community Medicine. For those patients, specialty use was 3 percent and 5 percent higher, respectively, during the first and second years after the medical home was implemented.

“This suggests a need for more effective co-management and better ‘handoffs’ of complex patients by primary care teams and specialists in the ‘medical neighborhood’ that surrounds the medical home,” Dr. Reid said. “We think new approaches to coordinating care between primary care teams and specialists should give priority to complex patients.”

A patient-centered medical home is an increasingly common way to amplify the effects of good primary care: It’s like having a family doctor who knows the patients and leads a team of professionals making the most of current knowledge and technology — including e-mail and electronic health records — to deliver first-rate, coordinated primary care and reach out to help patients stay healthy. Dr. Reid has published evaluations of Group Health’s medical home implementation, linking it to emergency room use.

Story Source:

The above story is based on materials provided by Group Health Research Institute. Note: Materials may be edited for content and length.

High Blood Pressure

  • DON’T  LEAVE  EMPTY-HANDED !!!

    Download your FREE Report on High Blood Pressure

    slide14t Just a sneak peek…

    • Choosing a healthy balanced diet
    • Electro-acupuncture treatments for hypertension
    • 10 common symptoms of high blood pressure
    • High blood pressure in children
    • Long-term complications of high blood pressure
    • How do diuretics work for high blood pressure?
    • Trans-fats are another cause of high blood pressure
    Download It Completely
    FREE

    Just Insert Your Name and email







    We will also send you a Complimentary copy of our High Blood Pressure Newsletter. Our newsletter subscription has the latest information on High Blood Pressure and Hypertension treatments.

    We respect your privacy. We will NEVER sell, rent or share your email address. That’s more than a policy, it’s our personal guarantee!

  • Now you can have the Latest News on High Blood Pressure

    hiblp02-220

    Worried about High Blood Pressure and Hypertension? You can have now information about the latest treatments and medical research. All this and more in our High Blood Pressure Newsletter.slide13t

    Try it for four weeks. We will even send you FREE our bonus health e-book with your trial subscription.

    All for just ONE PENNY

    Get the latest information – don’t be left in the dark on your condition.

     CLICK HERE 

    Check our special offer: Subscribe to one newsletter, get another newsletter for FREE!